METTL9

Summary

METTL9 (methyltransferase 9, His-X-His N1(pi)-histidine, HGNC:24586) is a protein-coding gene on chromosome 16p12.2, encoding Protein-L-histidine N-pros-methyltransferase (Q9H1A3). Protein-histidine N-methyltransferase that specifically catalyzes 1-methylhistidine (pros-methylhistidine) methylation of target proteins.

Enables protein-L-histidine N-pros-methyltransferase activity. Predicted to be involved in methylation. Is active in endoplasmic reticulum and mitochondrion.

Source: NCBI Gene 51108 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 26 total — 2 pathogenic
• MANE Select transcript: NM_016025

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24586
Approved symbol	METTL9
Name	methyltransferase 9, His-X-His N1(pi)-histidine
Location	16p12.2
Locus type	gene with protein product
Status	Approved
Aliases	DREV1
Ensembl gene	ENSG00000197006
Ensembl biotype	protein_coding
OMIM	609388
Entrez	51108

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 9 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000358154, ENST00000396014, ENST00000562379, ENST00000562961, ENST00000563026, ENST00000564733, ENST00000567404, ENST00000568826, ENST00000569290, ENST00000570074, ENST00000873751, ENST00000873752, ENST00000917718

RefSeq mRNA: 4 — MANE Select: NM_016025 NM_001077180, NM_001288659, NM_001288660, NM_016025

CCDS: CCDS10598, CCDS45440

Canonical transcript exons

ENST00000358154 — 5 exons

Exon	Start	End
ENSE00001908492	21599577	21599898
ENSE00003518508	21617865	21618074
ENSE00003551432	21612645	21612835
ENSE00003785518	21624931	21625115
ENSE00003844205	21655227	21657471

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 99.44.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 79.9190 / max 3778.2017, expressed in 1824 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
153108	78.2892	1824
153107	0.8696	595
153111	0.4280	156
153113	0.2293	89
153112	0.0590	27
153105	0.0437	21

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	99.44	gold quality
parotid gland	UBERON:0001831	99.14	gold quality
nephron tubule	UBERON:0001231	99.05	gold quality
monocyte	CL:0000576	99.03	gold quality
mononuclear cell	CL:0000842	99.03	gold quality
leukocyte	CL:0000738	98.95	gold quality
cortical plate	UBERON:0005343	98.80	gold quality
ganglionic eminence	UBERON:0004023	98.72	gold quality
oocyte	CL:0000023	98.67	gold quality
trabecular bone tissue	UBERON:0002483	98.66	gold quality
embryo	UBERON:0000922	98.64	gold quality
adrenal tissue	UBERON:0018303	98.61	gold quality
corpus epididymis	UBERON:0004359	98.56	gold quality
pigmented layer of retina	UBERON:0001782	98.55	gold quality
bone marrow	UBERON:0002371	98.42	gold quality
renal medulla	UBERON:0000362	98.39	gold quality
caput epididymis	UBERON:0004358	98.37	gold quality
kidney epithelium	UBERON:0004819	98.37	gold quality
ventricular zone	UBERON:0003053	98.30	gold quality
renal glomerulus	UBERON:0000074	98.15	gold quality
oral cavity	UBERON:0000167	98.13	gold quality
palpebral conjunctiva	UBERON:0001812	98.11	gold quality
metanephric glomerulus	UBERON:0004736	98.07	gold quality
cervix epithelium	UBERON:0004801	98.07	gold quality
mammalian vulva	UBERON:0000997	98.03	gold quality
amniotic fluid	UBERON:0000173	97.96	gold quality
esophagus squamous epithelium	UBERON:0006920	97.84	gold quality
kidney	UBERON:0002113	97.83	gold quality
metanephros	UBERON:0000081	97.80	gold quality
blood	UBERON:0000178	97.80	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	24.67
E-HCAD-10	yes	18.49
E-MTAB-9689	no	451.65
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

126 targeting METTL9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488

Literature-anchored findings (GeneRIF, showing 5)

• cloned the PAP1 gene, a p53 activated protein, from a U251-pTet-p53 cell line which carried a wild-type p53 transgene. (PMID:16837177)
• The methyltransferase METTL9 mediates pervasive 1-methylhistidine modification in mammalian proteomes. (PMID:33563959)
• METTL9 mediated N1-histidine methylation of zinc transporters is required for tumor growth. (PMID:34218407)
• siRNA screening identifies METTL9 as a histidine Npi-methyltransferase that targets the proinflammatory protein S100A9. (PMID:34562450)
• METTL9 derived circular RNA circ-METTL9 sponges miR-551b-5p to accelerate colorectal cancer progression by upregulating CDK6. (PMID:37158456)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mettl9	ENSDARG00000060001
mus_musculus	Mettl9	ENSMUSG00000030876
rattus_norvegicus	Mettl9	ENSRNOG00000025940
drosophila_melanogaster	CG5339	FBGN0034925
caenorhabditis_elegans		WBGENE00020199

Protein

Protein identifiers

Protein-L-histidine N-pros-methyltransferase — Q9H1A3 (reviewed: Q9H1A3)

Alternative names: DORA reverse strand protein, Methyltransferase-like protein 9

All UniProt accessions (7): Q9H1A3, H3BM54, H3BN86, H3BPE9, H3BQD2, H3BRP5, H3BTS9

UniProt curated annotations — full annotation on UniProt →

Function. Protein-histidine N-methyltransferase that specifically catalyzes 1-methylhistidine (pros-methylhistidine) methylation of target proteins. Specifically methylates the second His of proteins with a His-x-His (HxH) motif (where ‘x’ is preferably a small amino acid), while exploiting the first one as a recognition signature. Catalyzes methylation of target proteins such as S100A9, NDUFB3, SLC39A5, SLC39A7, ARMC6 and DNAJB12; 1-methylhistidine modification may affect the binding of zinc and other metals to its target proteins. Constitutes the main methyltransferase for the 1-methylhistidine modification in cell.

Subcellular location. Endoplasmic reticulum. Mitochondrion.

Similarity. Belongs to the METTL9 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H1A3-1	1	yes
Q9H1A3-2	2

RefSeq proteins (4): NP_001070648, NP_001275588, NP_001275589, NP_057109* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007884	METL9	Family
IPR029063	SAM-dependent_MTases_sf	Homologous_superfamily

Pfam: PF05219

Catalyzed reactions (Rhea), 1 shown:

• L-histidyl-[protein] + S-adenosyl-L-methionine = N(pros)-methyl-L-histidyl-[protein] + S-adenosyl-L-homocysteine + H(+) (RHEA:67076)

UniProt features (55 total): mutagenesis site 18, helix 14, strand 10, turn 4, binding site 3, sequence conflict 2, signal peptide 1, chain 1, glycosylation site 1, splice variant 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
7YF2	X-RAY DIFFRACTION	1.69
7Y9C	X-RAY DIFFRACTION	2.1
9VPQ	X-RAY DIFFRACTION	2.28
8GZF	X-RAY DIFFRACTION	2.5
7YF4	X-RAY DIFFRACTION	2.75
8GZE	X-RAY DIFFRACTION	3.4
7YF3	X-RAY DIFFRACTION	3.43

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H1A3-F1	83.68	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 174; 210; 295

Glycosylation sites (1): 35

Mutagenesis-validated functional residues (18):

Position	Phenotype
126	nearly abolished binding to substrate proteins.
151	abolished binding to s-adenosyl-l-homocysteine.
156	abolished binding to s-adenosyl-l-homocysteine.
173	decreased binding to s-adenosyl-l-homocysteine.
174	abolished protein-l-histidine n-pros-methyltransferase activity.
210	abolished binding to s-adenosyl-l-homocysteine.
213	abolished binding to substrate proteins.
214	decreased binding to slc39a5 substrate.
214	abolished binding to s-adenosyl-l-homocysteine and substrate proteins.
241	reduced binding to substrate proteins.
249	abolished binding to substrate proteins.
295	abolished binding to s-adenosyl-l-homocysteine.
297	reduced binding to substrate proteins.
300	abolished binding to substrate proteins.
306–308	abolished protein-l-histidine n-pros-methyltransferase activity.
115	decreased binding to s-adenosyl-l-homocysteine and substrate proteins.
118	decreased binding to s-adenosyl-l-homocysteine and substrate proteins.
123	abolished binding to substrate proteins.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 209 (showing top): GSE45365_NK_CELL_VS_BCELL_UP, AAGCAAT_MIR137, TTTGTAG_MIR520D, BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN, CEBPB_01, TGACATY_UNKNOWN, ZHANG_BREAST_CANCER_PROGENITORS_UP, MODULE_568, CTTTGTA_MIR524, MODULE_491, GOBP_METHYLATION, HUANG_DASATINIB_RESISTANCE_DN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, chr16p12, GARY_CD5_TARGETS_UP

GO Biological Process (1): methylation (GO:0032259)

GO Molecular Function (4): protein-L-histidine N-pros-methyltransferase activity (GO:0106370), protein binding (GO:0005515), methyltransferase activity (GO:0008168), transferase activity (GO:0016740)

GO Cellular Component (2): mitochondrion (GO:0005739), endoplasmic reticulum (GO:0005783)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
intracellular membrane-bounded organelle	2
metabolic process	1
N-methyltransferase activity	1
protein methyltransferase activity	1
S-adenosylmethionine-dependent methyltransferase activity	1
binding	1
transferase activity, transferring one-carbon groups	1
catalytic activity	1
endomembrane system	1

Protein interactions and networks

STRING

444 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
METTL9	IGSF6	O95976	972
METTL9	METTL25	Q8N6Q8	734
METTL9	METTL13	Q8N6R0	676
METTL9	TMT1B	Q6UX53	662
METTL9	METTL18	O95568	651
METTL9	METTL2B	Q6P1Q9	636
METTL9	METTL8	Q9H825	625
METTL9	METTL21C	Q5VZV1	585
METTL9	OTOA	Q7RTW8	575
METTL9	METTL24	Q5JXM2	572
METTL9	NTMT1	Q9BV86	567
METTL9	METTL27	Q8N6F8	558
METTL9	METTL17	Q9H7H0	532
METTL9	METTL25B	Q96FB5	530
METTL9	SETD3	Q86TU7	487

IntAct

87 interactions, top by confidence:

A	B	Type	Score
FAM20B	ASPHD2	psi-mi:“MI:0914”(association)	0.670
SLC1A1	AGPAT2	psi-mi:“MI:0914”(association)	0.640
SLC39A5	FAM171A2	psi-mi:“MI:0914”(association)	0.640
METTL9	MYG1	psi-mi:“MI:0915”(physical association)	0.560
SLC39A5	TMEM223	psi-mi:“MI:0914”(association)	0.530
LYPD6	PLXNB2	psi-mi:“MI:0914”(association)	0.530
SPRING1	PLSCR1	psi-mi:“MI:0914”(association)	0.530
SLC39A4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
SLC30A2	RER1	psi-mi:“MI:0914”(association)	0.530
FAM174A	BLTP3B	psi-mi:“MI:0914”(association)	0.530
CD70	METTL15	psi-mi:“MI:0914”(association)	0.530
SLC30A4	GOSR2	psi-mi:“MI:0914”(association)	0.530
TOR1A	TOR1B	psi-mi:“MI:0914”(association)	0.530
ARMC6	SLC27A2	psi-mi:“MI:0914”(association)	0.530
SLC30A2	ESYT2	psi-mi:“MI:0914”(association)	0.530
SLC30A4	OPA1	psi-mi:“MI:0914”(association)	0.530
METTL9	CHMP6	psi-mi:“MI:0915”(physical association)	0.370
METTL9	CHRM4	psi-mi:“MI:0915”(physical association)	0.370
PCNA	METTL9	psi-mi:“MI:0915”(physical association)	0.370
ORF69	PEPD	psi-mi:“MI:0914”(association)	0.350
SLC39A4	TMEM120B	psi-mi:“MI:0914”(association)	0.350
CHRNA9	TMEM120B	psi-mi:“MI:0914”(association)	0.350
CLEC2D	TMEM120B	psi-mi:“MI:0914”(association)	0.350
ST3GAL1	ITGAV	psi-mi:“MI:0914”(association)	0.350

BioGRID (101): METTL9 (Affinity Capture-RNA), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), METTL9 (Affinity Capture-MS)

ESM2 similar proteins: A0A1D5PUP4, A2AFS3, M0R7X9, O70472, O75882, O95803, P01134, P26012, P52799, P52848, P69849, Q02353, Q05204, Q0VCJ8, Q12841, Q13635, Q15155, Q3UHN9, Q3ZBS2, Q58D84, Q5EA46, Q5JPE7, Q5R9Y1, Q5U4X8, Q5VV63, Q5ZJB7, Q5ZMH6, Q61115, Q62356, Q62632, Q6A051, Q6GQK9, Q6GQT9, Q6P988, Q6UXG2, Q7Z5A7, Q86TD4, Q90693, Q91WE9, Q96CW9

Diamond homologs: Q0VCJ8, Q5ZMH6, Q9EPL4, Q9H1A3

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 106 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Metal ion SLC transporters	5	44.9×	9e-06
R-HSA-425366	5	13.5×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
zinc ion transmembrane transport	11	79.6×	2e-16
intracellular zinc ion homeostasis	10	49.6×	1e-12

Disease & clinical

Clinical variants and AI predictions

ClinVar

26 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	12
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1175706	NC_000016.9:g.(?21623965)(21730823_21968737)del	Pathogenic
685499	GRCh37/hg19 16p12.2(chr16:21597346-21741439)x1	Pathogenic

SpliceAI

1901 predictions. Top by Δscore:

Variant	Effect	Δscore
16:21612643:A:AG	acceptor_gain	1.0000
16:21612643:AGT:A	acceptor_gain	1.0000
16:21612644:G:GG	acceptor_gain	1.0000
16:21612644:GTG:G	acceptor_gain	1.0000
16:21618071:ACAG:A	donor_loss	1.0000
16:21618073:AGGTA:A	donor_loss	1.0000
16:21618074:GG:G	donor_loss	1.0000
16:21618075:GTATA:G	donor_loss	1.0000
16:21618076:T:G	donor_loss	1.0000
16:21624925:TTCTA:T	acceptor_loss	1.0000
16:21624926:TCTA:T	acceptor_loss	1.0000
16:21624928:TA:T	acceptor_loss	1.0000
16:21624929:A:AG	acceptor_gain	1.0000
16:21624929:AG:A	acceptor_loss	1.0000
16:21624930:G:GC	acceptor_gain	1.0000
16:21624930:GA:G	acceptor_gain	1.0000
16:21624930:GAGT:G	acceptor_gain	1.0000
16:21624930:GAGTC:G	acceptor_gain	1.0000
16:21625112:AACGG:A	donor_loss	1.0000
16:21625115:GGT:G	donor_loss	1.0000
16:21625116:G:A	donor_loss	1.0000
16:21625116:G:GG	donor_gain	1.0000
16:21625117:T:G	donor_loss	1.0000
16:21643072:A:AC	donor_gain	1.0000
16:21643073:C:CC	donor_gain	1.0000
16:21643073:CAGA:C	donor_gain	1.0000
16:21644283:GACTT:G	donor_loss	1.0000
16:21644284:ACTT:A	donor_loss	1.0000
16:21644285:CT:C	donor_loss	1.0000
16:21644286:TT:T	donor_loss	1.0000

AlphaMissense

2081 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:21612729:T:C	F84L	1.000
16:21612730:T:C	F84S	1.000
16:21612731:C:A	F84L	1.000
16:21612731:C:G	F84L	1.000
16:21617878:G:C	G124R	1.000
16:21617879:G:A	G124D	1.000
16:21617886:G:A	M126I	1.000
16:21617886:G:C	M126I	1.000
16:21617886:G:T	M126I	1.000
16:21617887:T:C	F127L	1.000
16:21617889:T:A	F127L	1.000
16:21617889:T:G	F127L	1.000
16:21617891:T:A	V128E	1.000
16:21617965:G:C	G153R	1.000
16:21617966:G:A	G153D	1.000
16:21617971:G:A	G155R	1.000
16:21617971:G:C	G155R	1.000
16:21617972:G:A	G155E	1.000
16:21617977:G:A	G157R	1.000
16:21617977:G:C	G157R	1.000
16:21617978:G:A	G157E	1.000
16:21617978:G:T	G157V	1.000
16:21618045:G:A	M179I	1.000
16:21618045:G:C	M179I	1.000
16:21618045:G:T	M179I	1.000
16:21618056:T:C	L183P	1.000
16:21624983:A:C	S207R	1.000
16:21624985:C:A	S207R	1.000
16:21624985:C:G	S207R	1.000
16:21624994:C:A	N210K	1.000

dbSNP variants (sampled 300 via entrez): RS1000065174 (16:21631613 G>A,C,T), RS1000074434 (16:21651162 G>T), RS1000197427 (16:21619379 A>G,T), RS1000246842 (16:21606118 C>T), RS1000298197 (16:21637866 G>A,C), RS1000307816 (16:21628365 T>C), RS1000353048 (16:21645206 A>G), RS1000354054 (16:21612856 T>A), RS1000364239 (16:21640839 A>G), RS1000371358 (16:21648367 C>T), RS1000422104 (16:21647954 C>T), RS1000491714 (16:21632557 G>A), RS1000505601 (16:21609045 C>T), RS1000545942 (16:21613850 A>G,T), RS1000569236 (16:21632816 T>G)

Disease associations

OMIM: gene MIM:609388 | disease phenotypes: MIM:607039

GenCC curated gene-disease

Mondo (1): autosomal recessive nonsyndromic hearing loss 22 (MONDO:0011762)

Orphanet (1): Rare autosomal recessive non-syndromic sensorineural deafness type DFNB (Orphanet:90636)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST005411_7	Thrombin-activatable fibrinolysis inhibitor activation peptide	5.000000e-07
GCST010146_3	Serum immune biomarker levels	4.000000e-10
GCST012291_1	Schizophrenia, bipolar disorder or recurrent major depressive disorder	6.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004869	YKL40 measurement
EFO:0004872	inflammatory biomarker measurement
EFO:0004952	disease recurrence

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C564633	Deafness, Autosomal Recessive 22 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, decreases methylation, decreases expression, increases methylation	2
Air Pollutants	decreases expression, increases abundance	2
Benzo(a)pyrene	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Valproic Acid	affects expression, decreases expression	2
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
butyraldehyde	decreases expression	1
ochratoxin A	increases expression	1
cupric chloride	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
NSC 689534	affects binding, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Temozolomide	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Cisplatin	increases expression	1
Copper	affects binding, decreases expression	1
Formaldehyde	decreases expression	1
Smoke	decreases expression, increases abundance	1
T-2 Toxin	decreases expression	1
Tetrachlorodibenzodioxin	affects cotreatment, increases expression	1
Tobacco Smoke Pollution	increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SY15	HAP1 METTL9 (-) 1	Cancer cell line	Male
CVCL_SY16	HAP1 METTL9 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.